MapLight Therapeutics, Inc.
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 6, 2026 | Guggenheim | initiate | — → Neutral | — | 52% |
| Aug 31, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Aug 10, 2026 | UBS | downgrade | Buy → Neutral | — | 54% |
| Jul 28, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Jul 28, 2026 | Morgan Stanley | downgrade | Overweight → Equal-Weight | — | 54% |
| Jul 28, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jul 24, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Jul 21, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Jul 21, 2026 | BMO Capital | initiate | — → Outperform | — | 53% |
| Jul 10, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Jun 25, 2026 | Raymond James | initiate | — → Strong Buy | — | 53% |
| Jun 23, 2026 | Craig-Hallum | maintain | Buy → Buy | — | 54% |
| Jun 22, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Jun 2, 2026 | Stifel | maintain | Buy → Buy | — | 53% |
| May 28, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 27, 2026 | UBS | initiate | — → Buy | — | 54% |
| May 21, 2026 | Craig-Hallum | initiate | — → Buy | — | 54% |
| May 4, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| Apr 8, 2026 | Needham | initiate | — → Buy | — | 50% |
| Apr 7, 2026 | TD Cowen | initiate | — → Buy | — | 54% |
| Mar 19, 2026 | Canaccord Genuity | initiate | — → Buy | $35 | 48% |
| Nov 21, 2025 | Jefferies | initiate | — → Buy | $32 | 51% |
| Nov 21, 2025 | Leerink Partners | initiate | — → Outperform | $30 | 51% |
| Nov 21, 2025 | Stifel | initiate | — → Buy | $28 | 53% |
| Nov 21, 2025 | Morgan Stanley | initiate | — → Overweight | $34 | 54% |
No cross-platform signals in the last 90 days